Adamas Pharmaceuticals Inc Form 4

March 24, 2015

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

**OMB APPROVAL** 

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires: 2005 Estimated average

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

1(b).

(Print or Type Responses)

1. Name and Ad Went Gregor	•	orting Person *	Issuer Name and Ticker or Trading     Symbol	5. Relationship of Reporting Person(s) to Issuer			
			Adamas Pharmaceuticals Inc [ADMS]	(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	_X_ Director _X_ 10% Owner _X_ Officer (give title Other (specify			
C/O ADAMAS			03/20/2015	below) below)  Chief Executive Officer			
PHARMACE	EUTICALS	, INC., 1900		Chief Executive Officer			
DOWELL OF CHIEF 750							

POWELL ST., SUITE 750

(State)

4. If Amendment, Date Original (Street)

(Zin)

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

#### EMERYVILLE, CA 94608

(City)

(City)	(State)	Tabl	e I - Non-D	<b>Derivative</b>	Secui	rities Acq	uired, Disposed o	f, or Beneficial	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securi or(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2015		M	100	A	\$ 1.875	10,108 (1)	D	
Common Stock	03/20/2015		S	100	D	\$ 18	10,008 (1)	D	
Common Stock	03/20/2015		S	200	D	\$ 18	405,980 (1)	I	Gregory T Went & Marjorie S Went ttees Went

Family

### Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

			Living Trust dtd 03/24/11
Common Stock	6,666	I	Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act
Common Stock	6,666	I	Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act
Common Stock	80,000	I	Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stock	80,000	I	Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went
Reminder: Report on a separate line for each class of securities beneficially owned directly or	indirectly.		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secur (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 1.875	03/20/2015		M	100	(2)	09/12/2016	Common Stock	100	\$

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Went Gregory T C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	X	X	Chief Executive Officer			

## **Signatures**

/s/Grace Shin, as Attorney-in-Fact 03/24/2015

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- (2) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3